

Seminars of the Hellenic Working Groups
February 18th-20°, 2010, Thessaloniki, Greece

Bi-Ventricular pacing after the most recent studies

Maurizio Lunati MD

Director EP Lab & Unit

Cardiology Dpt.

Niguarda Hospital

Milan – Italy

maurizio.lunati@ospedaleniguarda.it





ACC/AHA/HRS Guidelines 2008

Recommendations for CRT-D/P in Patients With Severe Systolic CHF (LVEF $\leq$ 35%)

Class I:

- QRS duration $\geq$ 120 ms
- Sinus rhythm
- NYHA III/ambulatory IV

Class IIa:

- QRS duration $\geq$ 120 ms; AF; NYHA III/ambulatory IV
- NYHA III/ambulatory IV; Frequent dependence on ventricular pacing

Class IIb:

- NYHA I/II; implantation of permanent pacing or ICD with anticipated frequent ventricular pacing

LVEF = left ventricular ejection fraction



Italian guidelines AIAC 2006

Cardiac Resynchronisation Therapy

Class I Indication

Sinus Rhythm, Reduced EF ($\leq 35\%$)
Ventricular Dyssynchrony (QRS $> 120\text{ms}$)
NYHA III-IV despite Optimal Medical Therapy

Class II Indications

Sinus Rhythm, Reduced EF ($\leq 35\%$)
Ventricular Dyssynchrony (QRS $> 120\text{ms}$)
Symptomatic (NYHA II) and with pacing indication or Primary Prevention ICD indication

Chronic Right Ventricular Pacing, Reduced EF ($\leq 35\%$)
Severe Ventricular Dyssynchrony
NYHA III-IV despite Optimal Medical Therapy

Pts In Atrial Fibrillation, Reduced EF ($\leq 35\%$)
Ventricular Dyssynchrony (QRS $> 120\text{ms}$)
NYHA III-IV despite Optimal Medical Therapy

Reduced EF ($\leq 35\%$), **QRS $\leq 120\text{ ms}$**
Ventricular Dyssynchrony (Echo assessment)
NYHA III-IV despite Optimal Medical Therapy



CRT: Open issues

- ✓ Patients in **I/II NYHA** functional class
- ✓ Patients with indication to **chronic right ventricular pacing**
- ✓ Patients with **chronic atrial fibrillation**
- ✓ Patients without **electrical dyssynchrony**



CRT: Open issues

- ✓ Patients in **I/II NYHA** functional class
- ✓ Patients with indication to chronic right ventricular stimulation
- ✓ Patients with chronic atrial fibrillation
- ✓ Patients without electrical dyssynchrony




Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure

William T. Abraham, MD; James B. Young, MD; Angel R. León, MD; Stuart Adler, MD; Alan J. Bank, MD; Shelley A. Hall, MD; Randy Lieberman, MD; L. Bing Liem, DO; John B. O'Connell, MD; John S. Schroeder, MD; Kevin R. Wheelan, MD; on behalf of the Multicenter InSync ICD II Study Group




CRT in NYHA II

186 pts in NYHA II, FE $\leq$ 35% and QRS $>$ 130ms randomized CRT ON vs CRT OFF



• CRT OFF (n=85)

Left Ventricular Ejection Fraction



End Point	CRT OFF	CRT ON	P
Change in peak VO2	0.2±3.2	0.5±3.2	0.87
Change in exercise duration, s	37±186	42±167	0.56
Change in NYHA	0.01±0.63	0.18±0.61	0.05
Change in QOL	10.7±21.7	13.3±25.1	0.49
Change in 6MHWt, m	33±98	38±109	0.59



CRT in NYHA II

Cardiac Resynchronization Therapy for the Treatment of Heart Failure in Patients With Intraventricular Conduction Delay and Malignant Ventricular Tachyarrhythmias

Steven L. Higgins, MD, FACC,* John D. Hummel, MD, FACC,† Imran K. Niazi, MD, FACC,‡
Michael C. Giudici, MD, FACC,§ Seth J. Worley, MD, FACC,|| Leslie A. Saxon, MD, FACC,¶
John P. Boehmer, MD, FACC,# Michael B. Higginbotham, MD,** Teresa De Marco, MD, FACC,¶
Elyse Foster, MD, FACC,¶ Patrick G. Yong, MSEE††

132 pts in NYHA I-II and QRS > 120ms (study subgroup)

End Point	NYHA Class I/II at Randomization		
	CRT	No CRT	p Value
Peak VO ₂ (ml/kg/min)	0.2 ± 0.3 (n = 120)	0.0 ± 0.3 (n = 121)	0.77
6 MW (m)	17 ± 9 (n = 125)	10 ± 9 (n = 130)	0.55
QOL (points)	-1 ± 2 (n = 127)	-4 ± 2 (n = 129)	0.26
NYHA class (%)	(n = 64)	(n = 68)	
Improved 2 classes	—	—	
Improved 1 class	9	16	0.84
No change	72	60	
Worsened	19	24	
LVID _d (mm)	-2.4 ± 0.8 (n = 124)	0.0 ± 0.8 (n = 117)	0.024
LVID _s (mm)	-3.2 ± 0.8 (n = 124)	-0.5 ± 0.8 (n = 117)	0.014
LVEF (%)	4.7 ± 0.9 (n = 123)	2.9 ± 0.9 (n = 125)	0.16




Versus Class III and IV Heart Failure (From the InSync/InSync ICD Italian Registry)

Maurizio Landolina^a MD, Maurizio Lunati^b MD, Maurizio Gasparini^c MD, Massimo Santini^d MD, Luigi Padeletti^e MD, Augusto Achilli^f MD, Stefano Bianchi^g MD, Francesco Laurenzi^h MD, Antonio Curnisⁱ MD, Antonio Vincenti^j MD, Sergio Valsecchi^k MS, Alessandra Denaro^k


CRT for NYHA II

952 pts analyzed: NYHA II (188 pts) vs NYHA III-IV (764)


Reduction of major CV events



NYHA class improvement with different %



Same reverse remodeling



CRT in NYHA I-II: REVERSE & MADIT CRT



2009:
The evidence!

CRT in NYHA II: REVERSE & MADIT CRT



REVERSE

presented
at ACC09

262 patients (Europe) followed for 24 months

Age (mean) yrs	61.3 ± 10.4
Ischemic	44%
NYHA II	83%
EF	27.1 ± 6.8
LVEDD (mm)	68.8 ± 9.2
QRS (ms)	156 ± 23
ICD therapy optional	68%

CRT OFF 82 Patients

CRT ON 180 Patients

MADIT-CRT

presented
at ESC 09

1820 patients (US&Europe) >30 months

Age (mean) yrs	N.A.
Ischemic	N.A.
NYHA	I+II
EF	≤30%
LVEDD (mm)	>55
QRS (ms)	>130
ICD therapy mandatory	100%


CRT OFF ~728 Patients

CRT ON ~1092 Patients

CRT in NYHA II: REVERSE




***Primary End Point:
Clinical Composite Response at 24-month
% worsened***



CRT in NYHA II: REVERSE



Powered Secondary End Point: *LVESVi*




CRT in NYHA II: REVERSE




Other Remodeling Parameters

LVEDVi (ml/m²)



LVEF (%)




P-value compares 24-month changes.



CRT in NYHA II: MADIT CRT confirms REVERSE

Improvements in LV function with CRT-D




Changes from baseline to 1-year follow-up



CRT in NYHA II: REVERSE



Other Secondary Endpoints: Functional Parameters




P-values compares 24-month changes.

P-value compares 24-month NYHA.

CRT in NYHA II: REVERSE



Time to First HF Hospitalization or Death



Number at Risk

CRT OFF

82

79

76

70

39

CRT ON

180

176

173

168


77

CRT in NYHA II:



MADIT CRT confirms REVERSE


*Primary endpoint:
Heart Failure or Death*






Predictive value of QRS: MADIT CRT-REVERSE

MADIT CRT



REVERSE 24-months





CRT in NYHA II: REVERSE & MADIT CRT

CRT reduces Morbidity and Mortality in asymptomatic HF Patients with LVD and wide QRS

REVERSE

Presented at ACC09

Presented results show that CRT

Significantly reduces time to first HF hospitalization or death¹ by 62 percent (HR 0.38 (0.20-0.73) p=0.003 within 24 months

¹ Note: time to First HF hospitalization or death" was not the primary endpoint

When compared to OMT, ICD optional

Daubert et al JACC 2009

MADIT-CRT

Presented at ESC

Presented results show that CRT is associated with a

Significant 34 percent reduction (p<0.001) in death or heart failure interventions within 33 months

When compared to OMT, ICD mandatory

Moss et al NEJM 2009



There is clear and solid evidence of
the benefits of **“Prophylactic CRT”**
in terms of clinical outcome and
ventricular remodeling



CRT: Open issues

- ✓ Patients in I/II NYHA functional class
- ✓ Patients with indication to **chronic right ventricular pacing**
- ✓ Patients with chronic atrial fibrillation
- ✓ Patients without electrical dyssynchrony

Advanced Biventricular Pacemakers to all Patients with AV-block?

A E Albertsen, J.C. Nielsen*, S.H. Poulsen*, H. Egeblad*, A.K. Peder-
sen*, P.S. Hansen*, H.K. Jensen*, P.T. Mortensen*

From the *Skejby University Hospital - Aarhus N - Denmark

CRT in pts with AV block



- 50 pts with complete A-V block and normal pump function
- randomized single site RV pacing or BIV pacing

Conclusions:

- ✓BIV pacing preserved LV pump function and minimized LV dyssynchrony as compared to conventional RV pacing;
- ✓LV pump function decreased significantly and LV dyssynchrony was more pronounced in the RV pacing group

Biventricular Pacing in Patients with Bradycardia and Normal Ejection Fraction



Cheuk-Man Yu, M.D., F.R.C.P., Joseph Yat-Sun Chan, F.H.K.A.M.,
Qing Zhang, M.M., Ph.D., Razali Omar, M.D.,
Gabriel Wai-Kwok Yip, M.D., F.A.C.C., Azlan Hussin, M.D., Fang Fang, Ph.D.,
Kai Huat Lam, M.B., B.S., Hamish Chi-Kin Chan, F.R.C.P.,
and Jeffrey Wing-Hong Fung, M.D., F.R.C.P.



CRT in pts with bradycardia

177 pts with bradycardia and normal EF implanted with a CRT device
Randomization 1:1 Biventricular pacing versus Right Ventricular Apical pacing

Primary end-point: LVEF and LVESV at 12 mos FU



Biventricular Pacing in Patients with Bradycardia and Normal Ejection Fraction


Cheuk-Man Yu, M.D., F.R.C.P., Joseph Yat-Sun Chan, F.H.K.A.M.,
Qing Zhang, M.M., Ph.D., Razali Omar, M.D.,
Gabriel Wai-Kwok Yip, M.D., F.A.C.C., Azlan Hussin, M.D., Fang Fang, Ph.D.,
Kai Huat Lam, M.B., B.S., Hamish Chi-Kin Chan, F.R.C.P.,
and Jeffrey Wing-Hong Fung, M.D., F.R.C.P.

CRT in pts with bradycardia




177 pts with bradycardia and normal EF implanted with a CRT device
Randomization 1:1 Biventricular pacing versus Right Ventricular Apical pacing

Subgroup analysis of LVEF



and LVESV



BioPace study

Randomized, multicentric, prospective, single-blind, parallel-group-design

International (EMEAC + Australia)

- 1st large scaled randomized study looking at the prevention of mechanical desynchronization
- Extend the benefit of BiV pacing to a broader patient population

Enrollment Goal

- 1800 patients @ 94 centers
- Follow-up phase

Evaluate whether patients with standard pacing indication (pacemaker or ICD)

- any standard-indication for permanent ventricular pacing
- LVEF without any limitation
- any QRS-width
- benefit from the prevention of ventricular remodeling (induced by RV pacing) with the implantation of a BiV pacing system

A landmark study which results will impact the future of pacemaker therapy



Biventricular pacing in patients with normal systolic function who should undergo conventional pacing (right ventricular apex) can prevent adverse left ventricular remodeling and reduction of left ventricular ejection fraction (PM-induced myopathy).



CRT: Open issues

- ✓ Patients in I/II NYHA functional class
- ✓ Patients with indication to chronic right ventricular stimulation
- ✓ Patients with **chronic atrial fibrillation**
- ✓ Patients without electrical dyssynchrony







Comparison of Usefulness of Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation and Heart Failure Versus Patients With Sinus Rhythm and Heart Failure

Peter Paul H.M. Delnoy, MD^{a,*}, Jan Paul Ottervanger, MD, PhD^a, Henk Oude Luttikhuis, MD^a, Arif Elvan, MD, PhD^a, Anand R. Ramdat Misier, MD, PhD^a, Willem P. Beukema, MD^a, and Norbert M. van Hemel, MD, PhD^b

CRT and AF

Evaluation of CRT in 263 consecutive pts, 96 with chronic AF and 167 in sinus rhythm





Four-Year Efficacy of Cardiac Resynchronization Therapy on Exercise Tolerance and Disease Progression


The Importance of Performing Atrioventricular Junction Ablation in Patients With Atrial Fibrillation

Maurizio Gasparini, MD,* Angelo Auricchio, MD, PhD,§§ François Regoli, MD,* Cecilia Fantoni, MD,‡ Mihoko Kawabata, MD,‡ Paola Galimberti, MD,* Daniela Pini, MD,* Carlo Ceriotti, MD,* Edoardo Gronda, MD,* Catherine Klersy, MD, MSc,† Simona Fratini, MD,‡ Helmut H. Klein, MD‡

CRT and AF

In 162 pts with permanent AF vs 511 pts in SR

162 pts with permanent AF where: 48 pts with rhythm control by drugs; 114 pts with AVJ ablation






CRT and AF

Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation

Kayvan Khadjooi, Paul Foley, Jeffrin Anthony, Shajil Chalil, Russell Smith, Michael Frenneaux and Francisco Leyva

In 86 pts with AF vs 209 pts in SR
86 pts with AF where: 66 permanent AF, 20 paroxysmal AF



Atrial fibrillation

224.1 (89.4)

203.3 (85.1) **

169.7 (80.2)

140.1 (76.1) ***

26.0 (11.8)

33.8 (11.0) ***

*, $p < 0.05$; **, $p < 0.001$; ***, $p < 0.0001$.



**Biventricular pacing is as effective
in patients with chronic atrial
fibrillation as in patients in sinus
rhythm.**



CRT: Open issues

- ✓ Patients in I/II NYHA functional class
- ✓ Patients with indication to chronic right ventricular stimulation
- ✓ Patients with chronic atrial fibrillation
- ✓ Patients without **electrical dyssynchrony**

Interventricular and intraventricular dyssynchrony are common in heart failure patients, regardless of QRS duration

Stefano Ghio^{a,*}, Cristina Constantin^a, Catherine Klersy^b, Alessandra Serio^a, Alessandra Fontana^a, Carlo Campana^a, Luigi Tavazzi^a

^a Division of Cardiology, IRCCS Policlinico San Matteo Hospital, V.le Golgi, 19 Pavia 27100, Italy





^b Biometry and Clinical Epidemiology, IRCCS San Matteo Hospital, Pavia, Italy

Received 11 April 2003; revised 3 September 2003; accepted 19 September 2003

QRS duration and dyssynchrony



QRS Duration and IVMD



Long-Term Effectiveness of Cardiac Resynchronization Therapy in Patients With Refractory Heart Failure and "Narrow" QRS

Augusto Achilli, MD,* Massimo Sassara, MD,* Sabina Ficili, MD,* Daniele Pontillo, MD,* Paola Achilli, MD,* Claudio Alessi, MD,* Stefano De Spirito, MD,* Roberto Guerra, MD,* Nicolino Patrino, MD,† Francesco Serra, MD*
Viterbo and Albano Laziale, Italy


CRT and narrow QRS




52 patients with severe HF and with echocardiographic evidence of interventricular and intraventricular asynchrony received biventricular pacing:

Group 1: QRS > 120 ms (38pts); Group 2: QRS ≤ 120 ms (14pts)

NYHA CLASS




6 MINUTES WALKING TEST




* p<0,001 vs baseline; ** p<0,01 vs baseline

EJECTION FRACTION



LVESD



Cardiac-Resynchronization Therapy in Heart Failure with Narrow QRS Complexes


John F. Beshai, M.D., Richard A. Grimm, D.O., Sherif F. Nagueh, M.D., James H. Baker II, M.D., Scott L. Beau, M.D., Steven M. Greenberg, M.D., Luis A. Pires, M.D., and Patrick J. Tchou, M.D., for the RethinQ Study Investigators*

CRT and narrow QRS



172 pts with narrow QRS ($<130\text{ms}$), $\text{EF} \leq 35\%$ and NYHA III

Randomization 1:1 CRT ON vs CRT OFF





We have no current guidance for doing something (CRT) in patients without wide QRS and dyssynchrony only.

The European cardiac resynchronization therapy survey



Kenneth Dickstein^{1,2}, Nigussie Bogale^{1,2*}, Silvia Priori³, Angelo Auricchio⁴, John G. Cleland⁵, Anselm Gitt⁶, Tobias Limbourg⁶, Cecilia Linde⁷, Dirk J. van Veldhuisen⁸, and Josep Brugada⁹ on behalf of the Scientific Committee and National Coordinators

The European cardiac resynchronization therapy (CRT) survey is a joint initiative taken by the Heart Failure Association and the European Heart Rhythm Association of the European Society of Cardiology. The primary aim of this survey is to describe current European practice associated with CRT implantations.

Table 1 Pre-implantation evaluation of the total cohort (n = 2438)

Demographics	
Age (years) ^a	70 (62–76)
Age ≥ 75 (%)	31
Females (%)	27
BMI (kg/m ²) ^a	26 (24–29)
Heart failure aetiology (%)	
Ischaemic	51
Non-ischaemic	40
Other	9
Clinical evaluation (%)	
NYHA I	2
NYHA II	20
NYHA III	70
NYHA IV	8
Mean LV ejection fraction (%)	27 ± 8
<25%	37
25–35%	46
>35%	17
LV end-diastolic diameter (mm)	65 ± 10
LV end-systolic diameter (mm)	54 ± 11

ECG (%)

Mean heart rate (b.p.m.)	72 ± 15
Sinus rhythm	73
Atrial fibrillation	23

QRS complex (%)

LBBB	68
RBBB	6
Paced rhythm	19
Mean QRS duration (msec)	157 ± 32
QRS duration < 120 ms	9
QRS duration 120 – 129 ms	10
QRS duration 130 – 149 ms	20
QRS duration ≥ 150 ms	62

The European cardiac resynchronization therapy survey



Kenneth Dickstein^{1,2}, Nigussie Bogale^{1,2*}, Silvia Priori³, Angelo Auricchio⁴, John G. Cleland⁵, Anselm Gitt⁶, Tobias Limbourg⁶, Cecilia Linde⁷, Dirk J. van Veldhuisen⁸, and Josep Brugada⁹ on behalf of the Scientific Committee and National Coordinators

Table 6 Comparison between COMPANION, CARE-HF, REVERSE and CRT Survey cohorts

	COMPANION	CARE-HF	REVERSE	CRT Survey
Number of patients	1212	409	419	2438
Patients with a CRT-P (%)	51	100	18	27
Patients with a CRT-D (%)	49	NA	82	73
Previous device (PPM or ICD) (%)	0 ^a	0 ^a	0 ^a	26
Mean age (years)	67	65	63	68
Women (%)	33	27	22	24
Ischaemic heart disease (%)	55	38	56	51
NYHA class III (%)	86	64	0 ^b	70
LV ejection fraction (%)	22	26	27	26
LV diastolic diameter (mm)	67	72	69	66
QRS (ms)	160	165	153	160
Atrial fibrillation (%)	0 ^a	0 ^a	0 ^a	23
Heart rate (b.p.m.)	72	70	67	70
Diuretics (%)	95	99	91	88
ARB/ACEI (%)	89	85	96	91
Betablockers (%)	68	72	96	85
Aldosterone antagonists (%)	54	56	NA	46


^aPrevious device implantation and atrial fibrillation were exclusion criteria. ^b NYHA class III/IV were exclusion criteria.



...our experience....


✓ 560 patients

✓ Mean age: $63,7 \pm 10,9$ yrs



Descrizione della popolazione CRT gestita

79% Maschi (443 pazienti) - Età media al 1° Impianto: 63 +/- 11 anni





Conclusions

Cardiac Resynchronisation Therapy

Class I Indication

Sinus Rhythm, Reduced EF ($\leq 35\%$)
Ventricular Dyssynchrony (QRS $> 120\text{ms}$)
NYHA III-IV despite Optimal Medical Therapy

Class II Indications

Sinus Rhythm, Reduced EF ($\leq 35\%$)

Strong evidence !!!

Prevention ICD indication

Chronic Right Ventricular Pacing Reduced EF ($< 35\%$)

Convincing evidence !

Strong evidence !!

NYHA III-IV despite Optimal Medical Therapy

Reduced EF ($\leq 35\%$) QRS $\leq 120\text{ms}$

Need of other RCTs

NYHA III-IV despite Optimal Medical Therapy



The future...

Babec's Story



*"On September 25th, 2004, the Birmingham Zoo successfully implanted the first cardiac resynchronization therapy device, or **CRT**, in a gorilla. One year later **Babec is still alive**, an unlikely scenario without the device, and **his quality of life is significantly improved** from that prior to surgery."*

Babec died in 2009...

5 years later CRT!!!